Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aroa Biosurgery's share price for the quarter that ended in Mar. 2024 was A$0.555. Aroa Biosurgery's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 344.21 Mil. Therefore, Aroa Biosurgery's market cap for the quarter that ended in Mar. 2024 was A$191.04 Mil.
Aroa Biosurgery's quarterly market cap
declined
from Mar. 2023 (A$360.26 Mil) to Sep. 2023 (A$269.60 Mil) and
declined
from Sep. 2023 (A$269.60 Mil) to Mar. 2024 (A$191.04 Mil).
Aroa Biosurgery's annual market cap
increased
from Mar. 2022 (A$265.41 Mil) to Mar. 2023 (A$360.26 Mil) but then
declined
from Mar. 2023 (A$360.26 Mil) to Mar. 2024 (A$191.04 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aroa Biosurgery's Enterprise Value for Today is A$175.29 Mil.
Aroa Biosurgery Market Cap Historical Data
The historical data trend for Aroa Biosurgery's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aroa Biosurgery's Market Cap
For the Medical Devices subindustry, Aroa Biosurgery's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Market Cap distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Market Cap falls into.
Aroa Biosurgery Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aroa Biosurgery's Market Cap for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aroa Biosurgery Market Cap Related Terms
Thank you for viewing the detailed overview of Aroa Biosurgery's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:ARX has been successfully added to your